The Claim
In obese mice, treatment with GLP-1 receptor agonists during weight loss results in a 20–55% reduction in liver mass that is proportionally greater than the reduction in skeletal muscle mass, indicating that liver metabolism is a primary target of these drugs.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice undergoing weight loss, drugs that activate GLP-1 receptors cause a larger decrease in liver size compared to muscle size, suggesting these drugs primarily affect how the liver processes energy.
See the scientific wording
In obese mice, GLP-1 receptor agonists reduce liver mass by 20–55% during weight loss, a greater proportional change than skeletal muscle, suggesting liver metabolism is a primary target of these drugs.
When the drug activates receptors in the liver, the liver starts burning fat faster and using up its stored sugar, which makes the liver shrink more than other parts of the body like muscles.
What the research says
1 studyWhen obese mice take GLP-1 drugs and lose weight, their livers get much smaller than their muscles, which means the drugs mainly work on the liver, not the muscles.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.